<DOC>
	<DOCNO>NCT00964678</DOCNO>
	<brief_summary>The purpose study determine whether carvedilol treatment patient pulmonary arterial hypertension associate right heart failure safe result improve function right heart .</brief_summary>
	<brief_title>Pilot Study Safety Efficacy Carvedilol Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>idiopathic , familial associate PAH , WHO group 1 NYHA class II III clinically stable optimized PAH treatment least 3 month minimal evidence fluid overload volume depletion , without diuretic treatment age &gt; 18 year mean pulmonary artery pressure ( mPAP ) &gt; 25 mmHg 6 minute walk distance ( 6MWD ) 100m Structural heart disease unrelated PAH Recent ( &lt; 3 month ) treatment intravenous positive inotropic agent current use βblockers history reactive airway disease history adverse reaction βblockers heart block ECG rest heart rate &lt; 60 bpm cardiac index &lt; 1.8 l/min/m2 systemic hypotension ( systolic pressure &lt; 90 mmHg ) pulmonary capillary wedge pressure &gt; 15 mmHg inability give inform consent contraindication CT and/or PET scan coagulopathy ( INR &gt; 1.5 platelet count &lt; 50000/mm3 ) severe renal insufficiency ( creatinine clearance &lt; 30 ml/min/m2 ) malignancy comorbidity limit survival condition predict inability complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>